MICHIGAN STATE
UNIVERSITY

Initial Study APPROVAL
Pre-2018 Common Rule

April 2, 2019

To: Lixin Zhang

Re: **MSU Study ID:** STUDY00001738
IRB: Biomedical and Health Institutional Review Board
Principal Investigator: Lixin Zhang
Category: Expedited 3, 5, 7
Submission: Initial Study STUDY00001738
Submission Approval Date: 4/1/2019
Effective Date: 4/1/2019
Study Expiration Date: 3/31/2020

Title: Intrapartum antibiotic prophylaxis and gram-negative neonatal sepsis in Palembang, Indonesia

This submission has been approved by the Michigan State University (MSU) Biomedical and Health Institutional Review Board. The submission was reviewed by the Institutional Review Board (IRB) through the Non-Committee Review procedure. The IRB has found that this study protects the rights and welfare of human subjects and meets the requirements of MSU's Federal Wide Assurance (FWA00004556) and the federal regulations for the protection of human subjects in research (e.g., pre-2018 45 CFR 46, 28 CFR 46, 21 CFR 50, 56, other applicable regulations).

How to Access Final Documents
To access the study's final materials, including those approved by the IRB such as consent forms, recruitment materials, and the approved protocol, if applicable, please log into the Click™ Research Compliance System, open the study's workspace, and view the "Documents" tab. To obtain consent form(s) stamped with the IRB watermark, select the "Final" PDF version of your consent form(s) as applicable in the "Documents" tab. Please note that the consent form(s) stamped with the IRB watermark must typically be used.

Continuing Review: IRB approval is valid until the expiration date listed above. If the research continues to involve human subjects, you must submit a Continuing Review request at least one month before expiration.

Modifications: Any proposed change or modification with certain limited exceptions discussed below must be reviewed and approved by the IRB prior to implementation of the change. Please submit a Modification request to have the changes reviewed. If changes are made at the time of continuing review, please submit a Modification and Continuing Review request.

Office of Regulatory Affairs
Human Research Protection Program

4000 Collins Road
Suite 136
Lansing, MI 48910

517-355-2180
Fax: 517-432-4503
Email: irb@msu.edu
www.hrpp.msu.edu

New Funding: If new external funding is obtained to support this study, a Modification request must be submitted for IRB review and approval before new funds can be spent on human research activities, as the new funding source may have additional or different requirements.

Immediate Change to Eliminate a Hazard: When an immediate change in a research protocol is necessary to eliminate a hazard to subjects, the proposed change need not be reviewed by the IRB prior to its implementation. In such situations, however, investigators must report the change in protocol to the IRB immediately thereafter.

Reportable Events: Certain events require reporting to the IRB. These include:

- Potential unanticipated problems that may involve risks to subjects or others
- Potential noncompliance
- Subject complaints
- Protocol deviations or violations
- Unapproved change in protocol to eliminate a hazard to subjects
- Premature suspension or termination of research
- Audit or inspection by a federal or state agency
- New potential conflict of interest of a study team member
- Written reports of study monitors
- Emergency use of investigational drugs or devices
- Any activities or circumstances that affect the rights and welfare of research subjects
- Any information that could increase the risk to subjects

Please report new information through the study's workspace and contact the IRB office with any urgent events. Please visit the Human Research Protection Program (HRPP) website to obtain more information, including reporting timelines.

Personnel Changes: Key study personnel must be listed on the MSU IRB application for expedited and full board studies and any changes to key study personnel must to be submitted as modifications. Although only key study personnel need to be listed on a non-exempt application, all other individuals engaged in human subject research activities must receive and maintain current human subject training, must disclose conflict of interest, and are subject to MSU HRPP requirements. It is the responsibility of the Principal Investigator (PI) to maintain oversight over all study personnel and to assure and to maintain appropriate tracking that these requirements are met (e.g. documentation of training completion, conflict of interest). When non-MSU personnel are engaged in human research, there are additional requirements. See HRPP Manual Section 4-10, Designation as Key Project Personnel on Non-Exempt IRB Projects for more information.

Prisoner Research: If a human subject involved in ongoing research becomes a prisoner during the course of the study and the relevant research proposal was not reviewed and approved by the IRB in accordance with the requirements for

research involving prisoners under subpart C of 45 CFR part 46, the investigator must promptly notify the IRB.

Site Visits: The MSU HRPP Compliance office conducts post approval site visits for certain IRB approved studies. If the study is selected for a site visit, you will be contacted by the HRPP Compliance office to schedule the site visit.

For Studies that Involve Consent, Parental Permission, or Assent Form(s):

Use of IRB Approved Form: Investigators must use the form(s) approved by the IRB and must typically use the form with the IRB watermark.

Copy Provided to Subjects: A copy of the form(s) must be provided to the individual signing the form. In some instances, that individual must be provided with a copy of the signed form (e.g. studies following ICH-GCP E6 requirements). Assent forms should be provided as required by the IRB.

Record Retention: All records relating to the research must be appropriately managed and retained. This includes records under the investigator's control, such as the informed consent document. Investigators must retain copies of signed forms or oral consent records (e.g., logs). Investigators must retain all pages of the form, not just the signature page. Investigators may not attempt to de-identify the form; it must be retained with all original information. The PI must maintain these records for a minimum of three years after the IRB has closed the research and a longer retention period may be required by law, contract, funding agency, university requirement or other requirements for certain studies, such as those that are sponsored or FDA regulated research. See HRPP Manual Section 4-7-A, Recordkeeping for Investigators, for more information.

Closure: If the research activities no longer involve human subjects, please submit a Continuing Review request, through which study closure may be requested. Human subject research activities are complete if there is no further interactions or interventions with human subjects and/or no further analysis of identifiable private information.

For More Information: See the HRPP Manual (available at hrpp.msu.edu).

Contact Information: If we can be of further assistance or if you have questions, please contact us at 517-355-2180 or via email at IRB@msu.edu. Please visit hrpp.msu.edu to access the HRPP Manual, templates, etc.

Expedited Category. Please see the appropriate research category below for the full regulatory text.

Expedited 1. Clinical studies of drugs and medical devices only when condition (a) or (b) is met.
(a) Research on drugs for which an investigational new drug application (21 CFR Part 312) is not required. (Note: Research on marketed drugs that significantly

increases the risks or decreases the acceptability of the risks associated with the use of the product is not eligible for expedited review.)
(b) Research on medical devices for which (i) an investigational device exemption application (21 CFR Part 812) is not required; or (ii) the medical device is cleared/approved for marketing and the medical device is being used in accordance with its cleared/approved labeling.

Expedited 2. Collection of blood samples by finger stick, heel stick, ear stick, or venipuncture as follows:
(a) from healthy, nonpregnant adults who weigh at least 110 pounds. For these subjects, the amounts drawn may not exceed 550 ml in an 8 week period and collection may not occur more frequently than 2 times per week; or
(b) from other adults and children, considering the age, weight, and health of the subjects, the collection procedure, the amount of blood to be collected, and the frequency with which it will be collected. For these subjects, the amount drawn may not exceed the lesser of 50 ml or 3 ml per kg in an 8 week period and collection may not occur more frequently than 2 times per week.

Expedited 3. Prospective collection of biological specimens for research purposes by noninvasive means.
Examples: (a) hair and nail clippings in a nondisfiguring manner; (b) deciduous teeth at time of exfoliation or if routine patient care indicates a need for extraction; (c) permanent teeth if routine patient care indicates a need for extraction; (d) excreta and external secretions (including sweat); (e) uncannulated saliva collected either in an unstimulated fashion or stimulated by chewing gumbase or wax or by applying a dilute citric solution to the tongue; (f) placenta removed at delivery; (g) amniotic fluid obtained at the time of rupture of the membrane prior to or during labor; (h) supra- and subgingival dental plaque and calculus, provided the collection procedure is not more invasive than routine prophylactic scaling of the teeth and the process is accomplished in accordance with accepted prophylactic techniques; (i) mucosal and skin cells collected by buccal scraping or swab, skin swab, or mouth washings; (j) sputum collected after saline mist nebulization.

Expedited 4. Collection of data through noninvasive procedures (not involving general anesthesia or sedation) routinely employed in clinical practice, excluding procedures involving x-rays or microwaves. Where medical devices are employed, they must be cleared/approved for marketing. (Studies intended to evaluate the safety and effectiveness of the medical device are not generally eligible for expedited review, including studies of cleared medical devices for new indications.)
Examples: (a) physical sensors that are applied either to the surface of the body or at a distance and do not involve input of significant amounts of energy into the subject or an invasion of the subject's privacy; (b) weighing or testing sensory acuity; (c) magnetic resonance imaging; (d) electrocardiography, electroencephalography, thermography, detection of naturally occurring radioactivity, electroretinography, ultrasound, diagnostic infrared imaging, doppler blood flow, and echocardiography; (e) moderate exercise, muscular strength testing, body composition assessment, and flexibility testing where appropriate given the age, weight, and health of the individual.

Expedited 5. Research involving materials (data, documents, records, or specimens) that have been collected, or will be collected solely for nonresearch purposes (such as medical treatment or diagnosis). (NOTE: Some research in this category may be exempt from the HHS regulations for the protection of human subjects. 45 CFR 46.101(b)(4). This listing refers only to research that is not exempt.)

Expedited 6. Collection of data from voice, video, digital, or image recordings made for research purposes.

Expedited 7. Research on individual or group characteristics or behavior (including, but not limited to, research on perception, cognition, motivation, identity, language, communication, cultural beliefs or practices, and social behavior) or research employing survey, interview, oral history, focus group, program evaluation, human factors evaluation, or quality assurance methodologies. (NOTE: Some research in this category may be exempt from the HHS regulations for the protection of human subjects. 45 CFR 46.101(b)(2) and (b)(3). This listing refers only to research that is not exempt.)

Expedited 8. Continuing review of research previously approved by the convened IRB as follows:
(a) where (i) the research is permanently closed to the enrollment of new subjects; (ii) all subjects have completed all research-related interventions; and (iii) the research remains active only for long-term follow-up of subjects; or
(b) where no subjects have been enrolled and no additional risks have been identified; or
(c) where the remaining research activities are limited to data analysis.

Expedited 9. Continuing review of research, not conducted under an investigational new drug application or investigational device exemption where categories two (2) through eight (8) do not apply but the IRB has determined and documented at a convened meeting that the research involves no greater than minimal risk and no additional risks have been identified.